Hematology NewsBALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patientsAugust 11, 2020CLLLeukemia, Myelodysplasia, Transplantation
Oncology PracticeEMA gives green light to avapritinib for GIST, acalabrutinib for CLLJuly 28, 2020GastroenterologyCLLLymphoma & Plasma Cell DisordersGastrointestinal Cancer
Hematology NewsIn remission for 10 years: Long-term toxicity data on CAR T cellsJuly 21, 2020CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIbrutinib-venetoclax produces high MRD-negative rates in CLL/SLLJune 23, 2020CLLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsThree-drug combo promising against high-risk CLLJune 15, 2020CLLLeukemia, Myelodysplasia, Transplantation
Oncology PracticeMCC response varies based on immunosuppression type, especially CLLJune 2, 2020Nonmelanoma Skin CancerCLL
Hematology NewsRace and location appear to play a role in the incidence of CLL and DLBCLMay 20, 2020CLLDLBCLLeukemia, Myelodysplasia, Transplantation
Hematology NewsInterleukin-27 increased cytotoxic effects of bone marrow NK cells in CLLMay 6, 2020CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsFDA approves ibrutinib-rituximab combo for newly diagnosed CLL, SLL in adultsApril 22, 2020CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsFive prognostic indexes come up short for planning early CLL treatmentApril 22, 2020CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsOne-third of high-risk CLL patients received treatment counter to recommendationsApril 8, 2020CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsCLL and breast cancer differ in the expression of regulatory microRNAsMarch 25, 2020CLLBreast Cancer
Hematology NewsNMA haploidentical allo-BMT plus post-transplant cyclophosphamide deemed safe, effective for CLLMarch 11, 2020CLLTransplant
Hematology NewsSafer CAR uses modified NK cells for advanced CLL, NHLFebruary 19, 2020TransplantCLLDLBCL
